
translumina
LIMITLESS POSSIBILITIES





New generation DES providing synergy of Biodegradable Polymer with microporous surface to enhance optimal performance.



Less Polymeric Load Compared to Other DES

One million pores per cm² with average depth of 2 µm ensures optimum drug release with **1/4th of polymeric load** as compared to other DES.

Shellac Resin (Wax-Free) ensures better polymer- drug biding with negligible polymer flaking during stent expansion

Yukon Choice PC Elite Sirolimus Eluting Coronary Stent System

PRODUCT MATRIX / ORDERING INFORMATION*

Stent Diameter	Stent length [mm] & Article number											
Ø [mm]	8 12		16	18	21	24	28	32				
Ø 2.00	YCET2008	YCET2012	YCET2016	YCET2018	YCET2021	YCET2024	YCET2028	YCET2032				
Ø 2.25	YCET2208	YCET2212	YCET2216	YCET2218	YCET2221	YCET2224	YCET2228	YCET2232				
Ø 2.50	YCET2508	YCET2512	YCET2516	YCET2518	YCET2521	YCET2524	YCET2528	YCET2532				
Stent Diameter	Stent length [mm] & Article number											
Ø [mm]	8	12	16	18	21	24	28	32				

Ø [mm]
 8
 12
 16
 18
 21
 24
 28
 32
 36
 40

 Ø 2.75
 YCET2708
 YCET2712
 YCET2716
 YCET2718
 YCET2718
 YCET2721
 YCET2724
 YCET2728
 YCET2732
 YCET2736
 YCET2740

 Ø 3.00
 YCET3008
 YCET3012
 YCET3016
 YCET3018
 YCET3021
 YCET3024
 YCET3028
 YCET3032
 YCET3036
 YCET3040

 Ø 3.50
 YCET3508
 YCET3512
 YCET3516
 YCET3518
 YCET3521
 YCET3524
 YCET3528
 YCET3532
 YCET3536
 YCET3540

 Ø 4.00
 YCET4008
 YCET4012
 YCET4016
 YCET4018
 YCET4021
 YCET4024
 YCET4028
 YCET4032
 YCET4036
 YCET4040

COMPLIANCE CHART

	Inflation Pressure (atm/bar/10 ⁵ Pa)														
Balloon Ø [mm]				NP (Nominal Pressure)							RBP (Rated Burst Pressure)				
	6	7	8	9	10	11	12	13	14	15		17	18	19	20
Ø 2.00	1.90	1.94	1.97	2.00	2.03	2.07	2.10	2.13	2.17	2.20	2.23	2.27	2.35	2.38	2.41
Ø 2.25	2.15	2.18	2.47	2.25	2.28	2.32	2.35	2.38	2.42	2.45	2.49	2.52	2.55	2.59	2.62
Ø 2.50	2.40	2.43	2.21	2.50	2.54	2.57	2.60	2.64	2.67	2.71	2.74	2.77	2.81	2.84	2.88
Ø 2.75	2.65	2.68	2.72	2.75	2.78	2.82	2.85	2.88	2.92	2.95	2.98	3.01	3.28	3.31	3.34
Ø 3.00	2.89	2.93	2.97	3.00	3.04	3.08	3.12	3.15	3.19	3.23	3.26	3.30	3.34	3.37	3.41
Ø 3.50	3.37	3.42	3.46	3.50	3.54	3.58	3.63	3.67	3.71	3.75	3.79	3.84	3.88	3.92	3.96
Ø 4.00	3.85	3.90	3.95	4.00	4.05	4.10	4.16	4.21	4.26	4.31	4.36	4.41	4.46	4.51	4.56

TECHNICAL DATA

riedical Stalliess Steel, Si	o Evin, Sarrace Containing	File Fores		
Crossing Profile	0.035" / 0.889 mm	Entry Profile	0.016" / 0.41 r	
Strut Thickness	0.0034" / 87 μm	Proximal Shaft Diameter	1.9 F	
Metallic Surface Area	13~19% depending on size	Distal Shaft Diameter	2.7 F	
Balloon Marker Material	Platinum / Iridium	Recommended Guide Wire	0.014"	
		Guiding Catheter	min. 5 F	

C €1434

Manufactured By:
Translumina Therapeutics LLP
Plot No. #12, Pharmacity, Selaqui, Dehradun 248011
(Uttarakhand) India
Manufacturing License No. MFG/MD/2019/000227

Registered Office: **Translumina Therapeutics LLP** Ground Floor, Metro Tower, LSC MOR Land, New Rajinder Nagar, New Delhi 110 060 - India

Under Technological Collaboration With: **Translumina GmbH**Neue Rottenburger Strasse 50, D-72379 Hechingen, Germany

CMC Medical Devices & Drugs S.L.


C/HoracioLengo N° 18, CP 29006, Málaga - Spain. Tel: +34951214054

Email: mmateos@cmcmedicaldevices.com | web: www.cmcmedicaldevices.com

Customer Care No: + 91 11-2874 2874
Email: info@translumina.in
Web: www.translumina.in for more details.

Please refer to the Instructions for Use supplied with these devices for indications, contraindications, Adverse Events, suggested procedures, warnings and precautions





Doc.Ref.No.YCET-BC Issue01, Revision

^{*} Please contact our Customer Care for available sizes



At 2 years, microporous surface was found to be equally safe as compared to electropolished surface. Rough surfaces showed lesser restenosis rates.



In Pre-clinical trial, it was seen that **Yukon Choice PC** with microporous surface reduced the amount of polymeric load to 1/4th and is assured with consistent kinetics & low inflammation.



World's Longest Studied Drug Eluting Stent



At four years follow up, **Yukon Choice PC** shows reduction of risk by 50% in Definite Stent Thrombosis & by 78% in Very Late stent thrombosis as compared to the first generation DES with similar efficacy.



International Journal of Cardiology, 168(6), 5162-51

At four years follow up, **Yukon Choice PC** demonstrated reduced rates in stent thrombosis in patients with diabetes mellitus as compared to durable polymer.



At 3 years, **Yukon Choice PC** proved equivalence to Xience in terms of Late loss, TLR and Primary Composite MACE.



proIntervention 2014;10-online published-ahead-of-print November 2014

Yukon Choice PC showed equivalent efficacy & better safety in terms of stent thrombosis compared to Xience & Cypher at 5 years follow up.





opean Heat Journal (2018) 00, 1-23

Yukon Choice PC is recommended by ESC guidelines 2018 on the basis of large randomized trials where primary end points were achieved.





At 10 years, **Yukon Choice PC** showed equivalence in terms of MACE rate, Mortality and TLR rate compared to Xience and a superiority over Cypher for the same outcomes.

Yukon Choice PC showed the lowest rate of definite or probable stent thrombosis with a significant risk reduction than the Cypher stent (50% reduction) and a numerically lower rate as than the 'Xience' stent (29% reduction).